bannerhome
 
 

ABOUT
US

Leadership Team

Frank Bedu Addo PDS

Frank Bedu-Addo, Ph.D.
Chief Executive Officer, Director

Dr. Bedu-Addo has served as a director, president and CEO of PDS Biotech since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.

Frank Bedu Addo PDS

Gregory Conn, Ph.D.
Chief Scientific Officer

Dr. Conn has more than 35 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of growth factors, work which led to the development and commercialization of the anti-cancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases of the drug development process, including FDA and regulatory requirements, is the co-inventor of eight drug patents, and was a founding member of the PDS team as CSO.

Frank Bedu Addo PDS

Michael King
Chief Financial Officer (Interim)

Mr. King joined PDS Biotech in 2014 as the Chief Financial Officer and took the company public via a reverse merger with Edge Therapeutics in March 2019. From the completion of the merger through his appointment as interim Chief Financial Officer in 2020, he served as a financial consultant to PDS Biotech. Mr. King is the former long-time Chief Business Officer and CFO of Aprecia Pharmaceuticals, a specialty pharmaceuticals company that develops branded specialty products using three-dimensional printing, a unique pharmaceutical manufacturing technology. He has served as a senior advisor to a number of early-stage public and private biotech companies. Mr. King was Chief Business Officer of Atrin Pharmaceuticals, Chief Commercial Officer of Belrose Pharma, as well as Head of US Product Portfolio & Strategy, and member of the US Executive Committee, for Sandoz GmbH, the $10 billion subsidiary of Novartis AG. A former management consultant with McKinsey & Company, Mr. King has a diverse background in corporate finance and sell-side analyst research, with deep knowledge of the pharmaceutical/biotech industry. Mr. King holds a Masters of Business Administration with Honors from the Columbia Graduate School of Business and a Bachelor of Arts from Wesleyan University.

Frank Bedu Addo PDS

Lauren V. Wood, M.D.
Chief Medical Officer

Dr. Wood joined PDS Biotech as Chief Medical Officer in February 2019.  She has overall responsibility for clinical development of the novel, immune activating Versamune® platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid tumors.  With 30 years of extensive clinical research experience at the National Institutes of Health, Dr. Wood most recently was the Clinical Director of the Vaccine Branch, Center for Cancer Research, National Cancer Institute.  While there she oversaw the translational development of immune-based therapies for both cancer and HIV infection and was a co-inventor of two patented therapeutic cancer vaccine platforms targeting the TARP and HER tumor antigens.Prior to joining the Vaccine Branch, Dr. Wood was a Senior Clinical Investigator from 1992-2009 in the NCI Pediatric Oncology and HIV and AIDS Malignancy Branches, overseeing teams investigating antiretroviral, anti-infective, and immunomodulatory therapies for HIV-infected children, adolescents and young adults.  Trained in both Internal Medicine and Pediatrics with subspecialty training in Allergy and Immunology from NIAID, Dr. Wood received her M.D. from Duke University School of Medicine and B.A. in Biology from Oberlin College.

Frank Bedu Addo PDS

Mark Baxter
Vice President of Global Quality

Dr. Baxter has more than 31 years of pharmaceutical Quality expertise, including quality oversight responsibilities ranging from early development through product commercialization. He is a graduate of Villanova University where he obtained a Ph.D., in Inorganic Chemistry studying binding constants between heavy metals and various carbohydrates. Dr. Baxter started his pharmaceutical career at Merck & Co., Inc., where he held various QC and QA leadership roles overseeing laboratory operations, sterile and non-sterile manufacturing and API production. Dr. Baxter held senior quality leadership roles at Schering-Plough where he oversaw all pharmaceutical quality operation activities throughout Europe and the Americas. More recently, Dr. Baxter held senior quality leadership roles in emerging biotech companies including Edge Therapeutics and Advaxis Immunotherapies.

Frank Bedu Addo PDS

Nathalie Riebel
Vice President of Clinical Operations

Mrs. Riebel joined PDS Biotech in June 2019 as the Vice President of Clinical Operations. She is responsible for the operational execution of the PDS Biotech pipeline. She brings 30 years of clinical research experience across the industry. Before joining PDS Biotech, Mrs. Riebel held a leadership role at Delcath Systems for oncology devices and Eli Lilly and Co. as Director of Global Quality/Inspection readiness. As Director of Clinical Operations at GSK, Imclone Systems, and ICON Clinical Research, she skillfully guided cross-functional global teams to achieve clinical deliverables and submissions.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf